News
Jun 16, 2014
CardioCell Scientific Advisory Board Member Presents at the 2014 Lugano Stem Cell Meeting
LUGANO, SWITZERLAND – LUGANO STEM CELL MEETING – June 16, 2014 – CardioCell LLC, a Stemedica Cell Technologies subsidiary that creates allogeneic stem-cell therapies for cardiovascular indications, announces a presentation by prominent chronic heart failure (HF) opinion leader Dr. Mihai Gheorghiade, a member of the company’s Scientific Advisory Board. Dr. Gheorghiade is professor of medicine and surgery and director of Experimental Therapeutics at the Center for Cardiovascular Innovation at Northwestern University’s Feinberg School of Medicine. He shares new insights on the “Potential Role of Stem Cell Therapy in Worsening Heart Failure” and discusses how he helped design the protocol for CardioCell’s upcoming Phase IIa clinical trial to use allogeneic stem-cell therapy to treat subjects with chronic HF.
|
Details: |
The Lugano Stem Cell Meeting convenes key opinion-leaders to discuss recent developments in the field of cardiac regeneration and heart cell therapy. Dr. Gheorghiade’s talk is part of the “Paracrine and Secreted Factors” session and covers the “Potential Role of Stem Cell Therapy in Worsening Heart Failure” and the significant progress in the cardiac regeneration field, as well as advances in prevention and treatment of cardiovascular disease in the past decade. |
|
When: |
Mon., June 23, 2014, at 3:20 p.m. CEST |
|
Where: |
Lugano Stem Cell Meeting |
|
Contact: |
Kimberly Stoddard, kimberly@townsendteam.com, (415) 805-5793 |
About CardioCell, LLC
Founded in San Diego, California, in 2013, CardioCell LLC is a global biotechnology company that explores therapeutic applications of unique, patented, ischemic-tolerant mesenchymal stem cells (itMSCs) manufactured under cGMP conditions. CardioCell is a subsidiary of Stemedica Cell Technologies Inc., a global biotechnology company that manufactures adult allogeneic stem cells. The company’s technology is based on more than 30 years of research and clinical experience conducted by scientists and physicians in Europe, the former Soviet Union and the United States. CardioCell therapies offer a unique, proprietary technology based on the expansion of cells in constant hypoxia, which provides critical benefits in terms of safety, efficacy and scalability. The company has an exclusive, worldwide license from Stemedica to explore therapeutic indications for unmet cardiovascular needs, such as acute myocardial infarction (AMI), chronic heart failure (CHF) and peripheral artery disease (PAD). For more information, visit www.stemcardiocell.com.